Cover Image
Market Research Report

Antacids Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 704963
Published Content info 111 Pages
Delivery time: 2-3 business days
Back to Top
Antacids Market - Growth, Trends, and Forecast (2019 - 2024)
Published: February 1, 2019 Content info: 111 Pages

Market Overview

The antacids market was valued at USD 8255.13 million in 2018, and it is expected to reach USD 10317.44 million by 2024, with an anticipated CAGR of 3.74% during the forecast period, 2019-2024. The propelling factors for the growth of the antacids market include the growing geriatric population suffering from GERD, poor lifestyle choices leading to higher incidences of acidity, and side effects of drugs like non-steroidal, anti-inflammatory drugs.

The group of people aged 60 years or higher is rising at a rate of approximately 3% every year and 65% of the geriatric population have to deal with acid reflux. This acts as one of the major factors boosting the antacid market globally. There has been an increase in the geriatric population and this is one of the most favorable growth factors for the antacids market as the demographic is highly vulnerable to peptic ulcers and gastroesophageal reflux disorders.

In the elderly population, the acidic complications recurrent infrequently, which makes it a unique challenge for both the primary care provider and the gastroenterologist. In addition, such patients often suffer from several symptomatic disorders, such as erosive esophagitis, Barrett esophagus, and esophageal cancer, in which a combination of therapies are used for the treatment and the use of antacids significantly rises in such cases.

In addition, there is also growth in e-commerce that is likely to augment the demand for antacids through online retailing channels over the next few years. Therefore, the rising popularity of e-commerce and surge in the number of online medicine providers are expected to positively impact the overall growth of the market.

Scope of the Report

As per the scope of the report, antacids are widely available medication used for slowing heartburn, sore stomach, acid indigestion, and stomach upset. It is helpful in protecting the stomach, duodenum, and esophagus from harsh acids released, while eating foods. The antacids generally do not require a prescription, in other words, they are self-prescribed. Therefore, they provide quick relief from heartburn, which is a major symptom of gastroesophageal reflux disease and indigestion.

Key Market Trends

Tablet is the Largest Segment Under Formulation Type that is expected to grow During the Forecast Years

Tablet has been estimated to be the largest segment due to the presence of chewable tablets in the market with different flavors that help to improve the patient adherence to the medication, which in turn is expected to contribute to the growth of the segment. Tablets also provide the correct amount of dosage to the patients and they are easy to store. These factors can be attributed to the segment growth over the forecast period.

In addition, the liquid dosage form is also one of the favored choices for children and the elderly population due to its pleasant taste. This factor is also anticipated to propel the market growth.

Asia-Pacific holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period

Asia-Pacific is expected to be the largest and fastest growing regional segment during the forecast period due to the high unmet clinical needs, availability of effective treatment methods, rising disposable income, and consumer awareness about the availability of these products. In addition, the presence of key players is anticipated to contribute to the market growth over the forecast period.

Competitive Landscape

The overall market faces intense competition over the forecast period due to the presence of multinational players and small-scaled companies. The other key growth strategies adopted by key players include strategic acquisitions, collaborations, and partnerships that will help them expand their geographical presence and will strengthen their business position as well.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 62826

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Geriatric Population Suffering from GERD
    • 4.2.2 Poor Lifestyle Choices Leading to Higher Incidences of Acidity
    • 4.2.3 Side Effects of Drugs like Non-Steroidal Anti-Inflammatory Drugs
  • 4.3 Market Restraints
    • 4.3.1 Ignorance of People towards Symptoms of Acidity
    • 4.3.2 Side Effects Related to Antacids like Acid Rebound
    • 4.3.3 Growing Number of Alternatives in the Market for Antacids
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Class
    • 5.1.1 Proton pump inhibitors
    • 5.1.2 H2 Antagonist
    • 5.1.3 Acid neutralizers
  • 5.2 By Formulation Type
    • 5.2.1 Tablet
    • 5.2.2 Liquid
    • 5.2.3 Powder
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Other Distribution Channels
  • 5.4 Geography
    • 5.4.1 North America
      • US
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Bayer AG
    • 6.1.3 Boehringer Ingelheim GmbH
    • 6.1.4 Dr. Reddy's Laboratories Ltd
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Sun Pharmaceuticals Ltd
    • 6.1.9 Reckitt Benckiser Group PLC
    • 6.1.10 Sanofi S.A


Back to Top